Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
作者： Sufi Mary Thomas , Jennifer Rubin Grandis
DOI: 10.1016/J.CTRV.2003.10.003
关键词:
摘要: … Preclinical and emerging pharmacokinetic and pharmacodynamic data for each of the anti-EGFR agents undergoing clinical investigation are discussed below. The level of detailed …
elsevier.com
sci-hub.se 参考文章(62)
Jonathan M. Bock, Shyh-Min Huang, Paul M. Harari, Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Research. ,vol. 59, pp. 1935- 1940 ,(1999)
Jim R Woodburn, Susan E Ashton, Simon P Guy, Keith H Gibson, Brenda J Curry, Andrew J Barker, Alan E Wakeling, ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Research. ,vol. 62, pp. 5749- 5754 ,(2002)
X.-D. Yang, A. Jakobovits, Ping Wang, C. G. Davis, X.-C. Jia, J. R. F. Corvalan, Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Research. ,vol. 59, pp. 1236- 1243 ,(1999)
Z Fan, Y Lu, X Wu, J Mendelsohn, Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. Journal of Biological Chemistry. ,vol. 269, pp. 27595- 27602 ,(1994) , 10.1016/S0021-9258(18)47026-3
Mark M. Moasser, Steven D. Averbuch, Neal Rosen, Andrea Basso, The Tyrosine Kinase Inhibitor ZD1839 ("Iressa") Inhibits HER2-driven Signaling and Suppresses the Growth of HER2-overexpressing Tumor Cells Cancer Research. ,vol. 61, pp. 7184- 7188 ,(2001)
Walter H.J. Ward, Peter N. Cook, Anthony M. Slater, D.Huw Davies, Geoffrey A. Holdgate, Leslie R'. Green, Epidermal growth factor receptor tyrosine kinase: Investigation of catalytic mechanism, structure-based searching and discovery of a potent inhibitor Biochemical Pharmacology. ,vol. 48, pp. 659- 666 ,(1994) , 10.1016/0006-2952(94)90042-6
Tony DeBlasio, Zhen Fan, Yang Lu, Ding Peng, John Mendelsohn, Howard Scher, Howard Scher, Anti-epidermal growth factor receptor monoclonal antibody 225 up-regulates p27KIP1 and induces G1 arrest in prostatic cancer cell line DU145. Cancer Research. ,vol. 56, pp. 3666- 3669 ,(1996)
Mark G. Kris, Howard I. Scher, Vincent A. Miller, Maureen F. Zakowski, Francis M. Sirotnak, Efficacy of Cytotoxic Agents against Human Tumor Xenografts Is Markedly Enhanced By Coadministration of ZD1839 (Iressa), an Inhibitor of EGFR Tyrosine Kinase Clinical Cancer Research. ,vol. 6, pp. 4885- 4892 ,(2000)
Peter Traxler, Elisabeth Buchdunger, Cheryl H. Baker, Rachel Tsan, Isaiah J. Fidler, Jerry J. Killion, Carmen C. Solorzano, Pamela Cohen, Optimization for the blockade of epidermal growth factor receptor signaling for therapy of human pancreatic carcinoma Clinical Cancer Research. ,vol. 7, pp. 2563- 2572 ,(2001)
Vincent A. Pollack, Catherine DiOrio, April Theleman, Elsa G. Barbacci, Leslie R. Pustilnik, Mark Neveu, Mikel P. Moyer, Kenneth K. Iwata, Lee Arnold, Michael J. Morin, James D. Moyer, Bruce Boman, Penny Miller, Ann Cunningham, Margaret M. Reynolds, Don Sloan, Jonathan Doty, Induction of Apoptosis and Cell Cycle Arrest by CP-358,774, an Inhibitor of Epidermal Growth Factor Receptor Tyrosine Kinase Cancer Research. ,vol. 57, pp. 4838- 4848 ,(1997)